Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient ...
EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback